Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiling Huaxian Fang (芪灵化纤方) is a Traditional Chinese Medicine (TCM) formula primarily investigated for its anti-fibrotic effects in chronic liver diseases. Developed by researchers at the Shanghai University of Traditional Chinese Medicine, the formula typically consists of *Astragalus membranaceus* (Huangqi), *Ganoderma lucidum* (Lingzhi), *Salvia miltiorrhiza* (Danshen), *Prunus persica* (Taoren), and *Curcuma zedoaria* (Ezhu). It is formulated based on the TCM principles of tonifying Qi and invigorating blood to resolve stasis. Pharmacological studies indicate that the formula exerts its therapeutic effects by modulating the TGF-β1/Smad signaling pathway, inhibiting the activation and proliferation of hepatic stellate cells, and promoting the degradation of collagen fibers in the liver parenchyma. It has been evaluated in clinical trials for patients with liver fibrosis and early-stage cirrhosis resulting from chronic hepatitis B infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qiling huaxian fang.